{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:30Z","timestamp":1793405310702,"version":"4.5.0"},"reference-count":77,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"Department of Defense Neurofibromatosis Research Program New Investigator Award","doi-asserted-by":"publisher","award":["W81XWH-22-1-0564"],"award-info":[{"award-number":["W81XWH-22-1-0564"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Exploration-Hypothesis Development Award","doi-asserted-by":"publisher","award":["NF220063"],"award-info":[{"award-number":["NF220063"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014804","name":"Neurofibromatosis Therapeutic Acceleration Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014804","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NF Michigan"},{"name":"Cancer Biology Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Plexiform neurofibromas associated with neurofibromatosis type I (pNF1s) are benign tumors caused by the complete loss of function of the NF1 gene, which encodes a negative regulator of the RAS\/mitogen-activated protein kinase (MAPK) pathway. pNF1s carry a significant risk of progression to malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive and largely incurable. FDA-approved mitogen-activated protein kinase kinase (MEK) inhibitors, selumetinib and mirdametinib, have shown ~30% tumor shrinkage in 70% and 42% pNF1 patients, respectively. However, not all pNF1s respond to MEK inhibition, and treatment is often associated with adverse effects such as dermatologic and gastrointestinal toxicities, underscoring the need for improved therapeutic strategies with minimal side effects. Here, we demonstrate that prolonged MEK inhibition increases proteolytic activity in 3D pNF1 tumor structures, consistent with enhanced extracellular matrix degradation. Prolonged treatment with four mechanistically and chemically distinct MEK inhibitors consistently reduced ERK phosphorylation, a downstream effector of the RAS\/MAPK pathway, yet induced adaptive phosphorylation of MEK and AKT in pNF1 tumor cells. Phosphorylation of MEK is required for its catalytic activation and subsequent phosphorylation of ERK. Increased MEK phosphorylation in the presence of MEK inhibitors reflects upstream pathway reactivation but does not lead to ERK phosphorylation and activation because of the presence of the inhibitor. This response was also observed in MPNST cell lines treated with MEK inhibitors. These findings suggest that adaptive activation of upstream and parallel survival pathways may counteract the intended effects of MEK inhibition and support the rationale for combination strategies to improve therapeutic outcomes in NF1-associated tumors.<\/jats:p>","DOI":"10.3390\/cells15050434","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:06:59Z","timestamp":1772467619000},"page":"434","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prolonged Mitogen-Activated Protein Kinase Kinase (MEK) Inhibition Induces Increase in Proteolysis and Compensatory Phosphorylation of MEK and Protein Kinase B (AKT) in Plexiform Neurofibroma Cells"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-265X","authenticated-orcid":false,"given":"Kyungmin","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA"},{"name":"Department of Pharmacology, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5564-355X","authenticated-orcid":false,"given":"John F.","family":"Callaghan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Brody Medical School, East Carolina University, Greenville, NC 27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Ridella","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-3861","authenticated-orcid":false,"given":"Raymond R.","family":"Mattingly","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Wayne State University, Detroit, MI 48201, USA"},{"name":"Department of Pharmacology and Toxicology, Brody Medical School, East Carolina University, Greenville, NC 27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2008.061051","article-title":"Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas","volume":"46","author":"Tucker","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","article-title":"Incidence and prevalence of neurofibromatosis type 1 and 2: A systematic review and meta-analysis","volume":"18","author":"Lee","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10072-021-05361-5","article-title":"Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): A systematic literature review","volume":"43","author":"Iheanacho","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40120-022-00365-5","article-title":"Burden Among Caregivers of Pediatric Patients with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibroma (PN) in the United States: A Cross-Sectional Study","volume":"11","author":"Yang","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/B978-0-444-64076-5.00051-X","article-title":"Neurofibromatosis type 1","volume":"Volume 148","author":"Cimino","year":"2018","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/1097-4547(20001215)62:6<755::AID-JNR1>3.0.CO;2-W","article-title":"Neurofibromatosis type 1. I. General overview","volume":"62","author":"Lakkis","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J. Med. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"White, E.E., and Rhodes, S.D. (2024). The NF1+\/\u2212 Immune Microenvironment: Dueling Roles in Neurofibroma Development and Malignant Transformation. Cancers, 16.","DOI":"10.3390\/cancers16050994"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"eadu0772","DOI":"10.1126\/sciadv.adu0772","article-title":"TGFbeta-dependent signaling drives tumor growth and aberrant extracellular matrix dynamics in NF1-associated plexiform neurofibroma","volume":"11","author":"Zhou","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1038\/s41388-021-01979-z","article-title":"Tumorigenesis in neurofibromatosis type 1: Role of the microenvironment","volume":"40","author":"Jiang","year":"2021","journal-title":"Oncogene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61500","DOI":"10.18632\/oncotarget.11133","article-title":"The role of nerve microenvironment for neurofibroma development","volume":"7","author":"Liao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ji, K., Shi, C., and Zhang, J. (2026). Mechanical Stiffening Promotes Growth, Invasion, and Mitogen-activated protein kinase kinase (MEK) Inhibitor Resistance in 3D Plexiform Neurofibroma Cultures. bioRxiv, preprint.","DOI":"10.64898\/2026.01.26.701794"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1017\/S1462399409001227","article-title":"Malignant peripheral nerve sheath tumour (MPNST): The clinical implications of cellular signalling pathways","volume":"11","author":"Katz","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lingo, J.J., Elias, E.C., and Quelle, D.E. (2025). Novel Therapeutics and the Path Toward Effective Immunotherapy in Malignant Peripheral Nerve Sheath Tumors. Cancers, 17.","DOI":"10.3390\/cancers17142410"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s13402-025-01054-9","article-title":"From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): A gaming among multiple factors","volume":"48","author":"Yu","year":"2025","journal-title":"Cell Oncol."},{"key":"ref_17","unstructured":"U.S. Food and Drug Administration (2020, April 13). FDA Approves Selumetinib for Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas."},{"key":"ref_18","unstructured":"U.S. Food and Drug Administration (2020, April 13). Drugs@FDA: FDA-Approved Drugs_KOSELUGO (Selumetinib), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process."},{"key":"ref_19","unstructured":"U.S. Food and Drug Administration (2025, February 11). FDA Approves Mirdametinib for Adult and Pediatric Patients with Neurofibromatosis Type 1 Who Have Symptomatic Plexiform Neurofibromas not Amenable to Complete Resection, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic#:~:text=On%20February%2011%2C%202025%2C%20the,not%20amenable%20to%20complete%20resection."},{"key":"ref_20","unstructured":"U.S. Food and Drug Administration (2025, February 11). Drugs@FDA: FDA-Approved Drugs_GOMEKLI (Mirdametinib), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=219379."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Armstrong, A.E., Belzberg, A.J., Crawford, J.R., Hirbe, A.C., and Wang, Z.J. (2023). Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10996-y"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children with Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100223","DOI":"10.1016\/j.esmoop.2021.100223","article-title":"Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: A comprehensive review","volume":"6","author":"Solares","year":"2021","journal-title":"ESMO Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.expneurol.2017.10.012","article-title":"Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening","volume":"299","author":"Kraniak","year":"2018","journal-title":"Exp. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ji, K., Schwenkel, G.J., Mattingly, R.R., Sundararaghavan, H.G., Zhang, Z.G., and Chopp, M. (2024). A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. Cancers, 16.","DOI":"10.3390\/cancers16142498"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Brassart-Pasco, S., Brezillon, S., Brassart, B., Ramont, L., Oudart, J.B., and Monboisse, J.C. (2020). Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00397"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: From mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00234-005-0033-4","article-title":"MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1","volume":"48","author":"Mautner","year":"2006","journal-title":"Neuroradiology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3340\/jkns.2025.0041","article-title":"Treatment of Plexiform Neurofibromas: Current Perspectives on Surgery and Medical Treatment","volume":"68","author":"Hwang","year":"2025","journal-title":"J. Korean Neurosurg. Soc."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Woodfield, S.E., Zhang, L., Scorsone, K.A., Liu, Y., and Zage, P.E. (2016). Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2199-z"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1124\/jpet.105.091454","article-title":"The mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines","volume":"316","author":"Mattingly","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/pbc.20565","article-title":"Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants","volume":"46","author":"Mahller","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ji, K., Zhao, Z., Sameni, M., Moin, K., Xu, Y., Gillies, R.J., Sloane, B.F., and Mattingly, R.R. (2021). Modeling Tumor: Lymphatic Interactions in Lymphatic Metastasis of Triple Negative Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13236044"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ji, K., and Schwenkel, G.J. (2025). Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. Cells, 14.","DOI":"10.3390\/cells14161276"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-4939-6850-3_16","article-title":"Live-Cell Imaging of Protease Activity: Assays to Screen Therapeutic Approaches","volume":"1574","author":"Chalasani","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Jedeszko, C., Sameni, M., Olive, M.B., Moin, K., and Sloane, B.F. (2008). Visualizing protease activity in living cells: From two dimensions to four dimensions. Current Protocols in Cell Biology, John Wiley & Sons, Inc.. Chapter 4.","DOI":"10.1002\/0471143030.cb0420s39"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0898-6568(01)00173-5","article-title":"Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells","volume":"13","author":"Mattingly","year":"2001","journal-title":"Cell Signal"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.canlet.2019.05.025","article-title":"AKT and ERK dual inhibitors: The way forward?","volume":"459","author":"Cao","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"180106","DOI":"10.1038\/sdata.2018.106","article-title":"Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells","volume":"5","author":"Ferrer","year":"2018","journal-title":"Sci. Data"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7150\/ijms.78386","article-title":"Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma","volume":"20","author":"Tian","year":"2023","journal-title":"Int. J. Med. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1038\/s41388-021-01773-x","article-title":"WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth","volume":"40","author":"Thomson","year":"2021","journal-title":"Oncogene"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Alewine, G., Knight, J., Ghantae, A., Mamrega, C., Attiah, B., Coover, R.A., and Fahrenholtz, C.D. (2022). Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner. J. Pers. Med., 12.","DOI":"10.3390\/jpm12071080"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.yexcr.2009.01.021","article-title":"Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation","volume":"315","author":"Rudy","year":"2009","journal-title":"Exp. Cell Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1083\/jcb.201103045","article-title":"Cortactin phosphorylation regulates cell invasion through a pH-dependent pathway","volume":"195","author":"Magalhaes","year":"2011","journal-title":"J. Cell Biol."},{"key":"ref_51","first-page":"e3661","article-title":"MAME models for 4D live-cell imaging of tumor: Microenvironment interactions that impact malignant progression","volume":"60","author":"Sameni","year":"2012","journal-title":"J. Vis. Exp."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.biochi.2015.09.015","article-title":"Pathomimetic cancer avatars for live-cell imaging of protease activity","volume":"122","author":"Ji","year":"2016","journal-title":"Biochimie"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12575-018-0085-6","article-title":"Three-Dimensional Quantification of Spheroid Degradation-Dependent Invasion and Invadopodia Formation","volume":"20","author":"Goertzen","year":"2018","journal-title":"Biol. Proced. Online"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"015001","DOI":"10.1088\/1478-3975\/aca0d8","article-title":"Proteolytic and mechanical remodeling of the extracellular matrix by invadopodia in cancer","volume":"20","author":"Perrin","year":"2022","journal-title":"Phys. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","article-title":"Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy","volume":"15","author":"Mai","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: From mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"176966","DOI":"10.1016\/j.ejphar.2024.176966","article-title":"Matrix metalloproteinases as the critical regulators of cisplatin response and tumor cell invasion","volume":"982","author":"Akhlaghipour","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00133486","article-title":"Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression","volume":"13","author":"Muir","year":"1995","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1158\/1078-0432.CCR-03-0712","article-title":"Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: Identification of a gene expression signature of poor prognosis","volume":"10","author":"Levy","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_60","first-page":"1359","article-title":"Expression of emmprin and matrix metalloproteinases (MMPs) in peripheral nerve sheath tumors: Emmprin and membrane-type (MT)1-MMP expressions are associated with malignant potential","volume":"26","author":"Nabeshima","year":"2006","journal-title":"Anticancer. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Vizovisek, M., Ristanovic, D., Menghini, S., Christiansen, M.G., and Schuerle, S. (2021). The Tumor Proteolytic Landscape: A Challenging Frontier in Cancer Diagnosis and Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052514"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Itoh, Y. (2022). Proteolytic modulation of tumor microenvironment signals during cancer progression. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.935231"},{"key":"ref_63","first-page":"712","article-title":"Cancer\u2014Proteases in Progression and Metastasis","volume":"Volume 6","author":"Bradshaw","year":"2023","journal-title":"Encyclopedia of Cell Biology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1593\/neo.13946","article-title":"Acid-mediated tumor proteolysis: Contribution of cysteine cathepsins","volume":"15","author":"Rothberg","year":"2013","journal-title":"Neoplasia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13058-017-0847-0","article-title":"Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ","volume":"19","author":"Sameni","year":"2017","journal-title":"Breast Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"113042","DOI":"10.1016\/j.celrep.2023.113042","article-title":"Ectopic expression of DOCK8 regulates lysosome-mediated pancreatic tumor cell invasion","volume":"42","author":"Johnson","year":"2023","journal-title":"Cell Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"101989","DOI":"10.1016\/j.molmet.2024.101989","article-title":"Cathepsin D is essential for the degradomic shift of macrophages required to resolve liver fibrosis","volume":"87","author":"Pistorio","year":"2024","journal-title":"Mol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/s41388-025-03582-y","article-title":"Adaptive cancer therapy: Can non-genetic factors become its achilles heel?","volume":"44","author":"Valcz","year":"2025","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Gu, Y., Wang, W., Li, Y., Li, H., Guo, Z., Wei, C., Long, M., Chung, M., Aimaier, R., and Li, Q. (2022). Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.903177"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","article-title":"MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors","volume":"72","author":"Turke","year":"2012","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e10988","DOI":"10.15252\/msb.202210988","article-title":"Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance","volume":"19","author":"Frohlich","year":"2023","journal-title":"Mol. Syst. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Puranik, N., Jung, H., and Song, M. (2024). SPROUTY2, a Negative Feedback Regulator of Receptor Tyrosine Kinase Signaling, Associated with Neurodevelopmental Disorders: Current Knowledge and Future Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252011043"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/13543784.2025.2599455","article-title":"Developments of MEK inhibitors as future cancer therapies: What have we learned from preclinical and clinical studies?","volume":"34","author":"Petrini","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41392-022-01038-3","article-title":"Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy","volume":"7","author":"Pan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1158\/1078-0432.CCR-16-1323","article-title":"NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability","volume":"23","author":"Palanichamy","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Callaghan, J.F., and Mattingly, R.R. (2025). Challenges and Progress for Treatment of Malignant Peripheral Nerve Sheath Tumors in the Context of Recent Successes for Sarcoma Therapy. Cancers, 17.","DOI":"10.3390\/cancers17233781"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/5\/434\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:29:31Z","timestamp":1772515771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/5\/434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":77,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cells15050434"],"URL":"https:\/\/doi.org\/10.3390\/cells15050434","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}